Luminex Corp Valuation – Initial Coverage $LMNX

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Stocks for Using A Benjamin Graham Value Investing Strategy – March 2017.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Luminex Corp (LMNX) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease.

LMNX Chart

LMNX data by YCharts

To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Recent valuations of the components of the Dow Jones Industrial Average are available for free members, including this one of Microsoft Corporation.  In addition, here is a post detailing what can be found within each individual company’s valuation.

[otw_shortcode_button href=”” size=”medium” icon_position=”left” shape=”square”]Learn More About Premium Membership[/otw_shortcode_button]


Downloadable PDF version of this valuation:

ModernGraham Valuation of LMNX – March 2017

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $743,603,870 Fail
2. Sufficiently Strong Financial Condition Current Ratio > 2 4.32 Pass
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 107.94% Pass
6. Moderate PEmg Ratio PEmg < 20 41.65 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 1.93 Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 4.32 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 0.00 Pass
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Fail
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

EPSmg $0.44
MG Growth Estimate 11.23%
MG Value $13.50
Opinion Overvalued
MG Grade C-
MG Value based on 3% Growth $6.32
MG Value based on 0% Growth $3.71
Market Implied Growth Rate 16.58%
Current Price $18.16
% of Intrinsic Value 134.53%

Luminex Corporation is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the small size, poor dividend history, and the high PEmg ratio. The Enterprising Investor is only concerned with the lack of dividends. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $0.25 in 2013 to an estimated $0.44 for 2017. This level of demonstrated earnings growth does not support the market’s implied estimate of 16.58% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Luminex Corporation revealed the company was trading above its Graham Number of $5.21. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 41.65, which was above the industry average of 32.29. Finally, the company was trading above its Net Current Asset Value (NCAV) of $2.95.

Luminex Corporation receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) $2.95
Graham Number $5.21
PEmg 41.65
Current Ratio 4.32
PB Ratio 1.93
Current Dividend $0.00
Dividend Yield 0.00%
Number of Consecutive Years of Dividend Growth 0


Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2016
Total Current Assets $173,737,000
Total Current Liabilities $40,200,000
Long-Term Debt $0
Total Assets $450,716,000
Intangible Assets $173,889,000
Total Liabilities $47,037,000
Shares Outstanding (Diluted Average) 43,013,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $0.13
Dec2016 $0.32
Dec2015 $0.86
Dec2014 $0.93
Dec2013 $0.17
Dec2012 $0.30
Dec2011 $0.34
Dec2010 $0.12
Dec2009 $0.43
Dec2008 $0.08
Dec2007 -$0.08
Dec2006 $0.05
Dec2005 -$0.09
Dec2004 -$0.12
Dec2003 -$0.14
Dec2002 -$0.85
Dec2001 -$0.55
Dec2000 -$0.52
Dec1999 -$0.96
Dec1998 -$0.43

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $0.44
Dec2016 $0.56
Dec2015 $0.63
Dec2014 $0.47
Dec2013 $0.25
Dec2012 $0.28
Dec2011 $0.24
Dec2010 $0.16
Dec2009 $0.15
Dec2008 $0.00
Dec2007 -$0.06
Dec2006 -$0.11
Dec2005 -$0.24
Dec2004 -$0.36
Dec2003 -$0.52
Dec2002 -$0.69
Dec2001 -$0.57

Recommended Reading:

Other ModernGraham posts about the company

None. This is the first time ModernGraham has covered the company.

Other ModernGraham posts about related companies

LHC Group Inc Valuation – Initial Coverage $LHCG
Dentsply Sirona Inc Valuation – March 2017 $XRAY
Landauer Inc Valuation – Initial Coverage $LDR
IDEXX Laboratories Inc Valuation – Initial Coverage $IDXX
Hologic Inc Valuation – Initial Coverage $HOLX
Mettler-Toledo International Inc Valuation – Initial Coverage $MTD
Envision Healthcare Corp Valuation – Initial Coverage $EVHC
UnitedHealth Group Inc Valuation – February 2017 $UNH
Davita Inc Valuation – February 2017 $DVA
Steris PLC Valuation – Initial Coverage $STE


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.